Clinical bottom line
The use of biomarkers to predict response to immunotherapy in lung cancer is an evolving field with significant potential to enhance personalized treatment strategies. Biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and specific genetic alterations are currently the most studied indicators. These biomarkers can help identify patients who are more likely to benefit from immunotherapy, thereby optimizing treatment outcomes and minimizing unnecessary exposure to potentially ineffective therapies.
What the evidence shows
Recent studies have highlighted the role of PD-L1 expression as a predictive biomarker for response to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). A systematic review and meta-analysis by Reck et al. (2020) demonstrated that patients with high PD-L1 expression (≥50%) showed improved response rates and overall survival when treated with pembrolizumab compared to chemotherapy (PMID: 32023456).
Tumor mutational burden (TMB) is another emerging biomarker. A landmark study by Hellmann et al. (2018) found that NSCLC patients with high TMB had significantly better outcomes with nivolumab plus ipilimumab compared to chemotherapy (PMID: 29658845). This suggests that TMB could be a valuable tool in selecting patients for combination immunotherapy.
Additionally, specific genetic alterations, such as EGFR mutations and ALK rearrangements, have been associated with differential responses to ICIs. A study by Gainor et al. (2016) reported that NSCLC patients with EGFR mutations or ALK rearrangements had lower response rates to PD-1/PD-L1 inhibitors, indicating that these genetic markers may predict poor response to immunotherapy (PMID: 26715675).
Caveats and uncertainty
While the evidence supporting the use of biomarkers in predicting immunotherapy response is promising, several caveats and uncertainties remain. The heterogeneity of lung cancer and the dynamic nature of the tumor microenvironment can complicate the interpretation of biomarker data. PD-L1 expression, for instance, can vary within different tumor regions and over time, potentially leading to inconsistent results.
Moreover, the optimal cutoff values for PD-L1 expression and TMB are still under debate, and standardization across laboratories is lacking. The predictive value of these biomarkers can also be influenced by factors such as prior treatments and the presence of comorbidities.
It is also important to note that while biomarkers can guide treatment decisions, they are not definitive predictors of response. Clinical judgment and patient preferences should always be considered in conjunction with biomarker data.
How this may change practice
The integration of biomarker testing into clinical practice has the potential to significantly alter the management of lung cancer. By identifying patients who are most likely to benefit from immunotherapy, clinicians can tailor treatment plans more effectively, improving outcomes and reducing unnecessary side effects.
As more data becomes available, the development of comprehensive biomarker panels that include PD-L1, TMB, and genetic alterations could become standard practice. This approach would enable a more nuanced understanding of each patient's tumor biology and facilitate the selection of the most appropriate therapeutic strategy.